Drugs / ONC-783
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT07408258 | Jun 2026 → Jun 2027 expected | neoplasm | OncoC4, Inc. | Not yet recruiting | No outcome recorded |
Press releases naming this drug 1 release
| Date | Issuer | Release |
|---|---|---|
| 2026-08-17 | OncoC4, Inc. | OncoC4 Announces First Patient Dosing in Phase 1 Clinical Trial of ONC-783 for the Treatment of Advanced Solid Tumors oncoc4.com ↗ |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | ONC-783 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07408258 ↗ |
| Modality | Monoclonal antibody | “ONC-783 is a bispecific humanized monoclonal antibody targeting CD24 and CD3.” NCT07408258 ↗ |
| Route | Subcutaneous | “ONC-783 will be given by SC injection with designated dose levels at Day 1 of each cycle.” NCT07408258 ↗ |